LAKE FOREST, Calif., Jan. 26, 2015 /PRNewswire/ -- Cryoport, Inc. (OTCBB: CYRX) ("Company"), the leading provider of advanced cryogenic logistics solutions for life sciences serving markets including immunotherapies, stem cells, cell lines, clinical research organizations, vaccine manufacturers, and reproductive medicine, today announced the expansion and restructuring of its national sales force in the United States.
Cryoport's Chief Commercial Officer, Mark W. Sawicki, Ph.D., announced changes to the US sales organization, which includes a restructuring of territories and the addition of five new Sales Directors with more than 120 years of aggregated experience in the fields of cold chain logistics, healthcare, clinical trial management and life sciences. These new Sales Directors will play a critical role in building upon and accelerating Cryoport's record of growth and innovation as the leading provider of cryogenic logistics solutions to the life sciences. This expansion will significantly enhance the existing sales efforts and better enable Cryoport to meet the rapidly growing demand for frozen logistics solutions by the life sciences industry at large.
Mark Sawicki states, "The life sciences industry is entering a new, era of innovation, including advances in biopharmaceuticals, immunotherapies, vaccinations and regenerative medicine. As the premier cryogenic logistics provider and the preferred partner of the world's largest shipping companies, Cryoport is continuously innovating and evolving to meet the needs of a life sciences industry where secure, track-able cryogenic transfer of biomaterials is either mandated or mission critical. With this expansion of our sales team, Cryoport is better positioned than ever before to capitalize on the fastest growing segments of the market, such as stem cells and CAR-T Cell therapies.
Jerrell Shelton, CEO of Cryoport, commented, "The life sciences industry continues to evolve and exhibit explosive growth globally. The fact that most new cell based products must be shipped in controlled cryogenic conditions and many of the new critical experimental vaccines for Ebola and Malaria require cryogenic solutions to support vaccine efficacy and distribution into regions with limited infrastructure creates an abundance of opportunities for Cryoport. With regulatory requirements becoming increasingly stringent and cryogenic shipping now mandated for many new therapeutic areas, the addition of these highly skilled and experienced personnel to our sales force will enable us to capitalize on what we see as an unprecedented market opportunity where Cryoport is already recognized as the clear leader with unique competencies."
About Cryoport, Inc.
Cryoport provides leading edge frozen logistics solutions to the life sciences industry through the combination of purpose-built proprietary packaging, information technology and specialized cold chain logistics expertise. Its competencies range from skilled, total turnkey management of the entire life sciences cold chain logistics process to complex total management solutions for outsourced cold chain logistics.
Its packaging, built around its Cryoport Express® liquid nitrogen dry vapor shippers, is validated to maintain a constant -150°C temperature for a 10-plus day dynamic shipment duration. Its information technology boasts a Cryoportal™ Logistics Management Platform which manages the entire shipment process, including initial order input, document preparation, customs clearance, integrator/courier management, shipment tracking, issue resolution, and delivery. Cryoport uses recyclable and reusable components providing an environmentally friendly solution. Cryoport solutions can record the "chain of condition" and "chain of custody" for shipments thereby meeting the exacting requirements for scientific work and for regulatory purposes. For more information, visit www.cryoport.com.
Forward Looking Statements
Statements in this news release which are not purely historical, including statements regarding Cryoport, Inc.'s intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, risks and uncertainties associated with the effect of changing economic conditions, trends in the products markets, variations in the company's cash flow, market acceptance risks, and technical development risks. The company's business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended March 31, 2013. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Cryoport, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.
SOURCE Cryoport, Inc.